Add to ORKGEffi cacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled tria
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). B...
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune...
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune...
Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet de...
Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet de...
Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet de...
Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura (ITP)
Immune Thrombocytopenic Purpura (ITP) has long been thought to result predominantly from immune medi...
Romiplostim is a peptibody, which stimulates platelet production by a mechanism similar to that of e...
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children wit...
Prakash Vishnu,1 David M Aboulafia1,2 1Floyd and Delores Jones Cancer Institute at Virginia Mason Me...
Romiplostim was effective, safe, and well-tolerated over 6 – 12 months of continuous treatment in Ph...
This case report describes a patient with relapsed primary immune thrombocytopenic purpura (ITP), in...
<p>Romiplostim was effective, safe, and well-tolerated over 6–12 months of continuous treatment in P...
Patients with Immune thrombocytopenic purpura (ITP) often require immunoglobulin (Ig) therapy with i...
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). B...
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune...
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune...
Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet de...
Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet de...
Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet de...
Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura (ITP)
Immune Thrombocytopenic Purpura (ITP) has long been thought to result predominantly from immune medi...
Romiplostim is a peptibody, which stimulates platelet production by a mechanism similar to that of e...
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children wit...
Prakash Vishnu,1 David M Aboulafia1,2 1Floyd and Delores Jones Cancer Institute at Virginia Mason Me...
Romiplostim was effective, safe, and well-tolerated over 6 – 12 months of continuous treatment in Ph...
This case report describes a patient with relapsed primary immune thrombocytopenic purpura (ITP), in...
<p>Romiplostim was effective, safe, and well-tolerated over 6–12 months of continuous treatment in P...
Patients with Immune thrombocytopenic purpura (ITP) often require immunoglobulin (Ig) therapy with i...
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). B...
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune...
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune...